Drug reference
atoltivimab
Ebola virus infection treatment
Ebola virus infection treatment
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Atoltivimab is part of a cocktail of three monoclonal antibodies (atoltivimab/maftivimab/odesivimab) that together effectively treat Ebola virus infection. The cocktail demonstrated a reduction in mortality in clinical trials.
Indications
treatment of Ebola virus infection (as part of a cocktail)treatment of Zaire ebolavirus (as part of Inmazeb)Ebola disease in PCR-confirmed adults (including pregnant women) and children
Pharmacokinetics
Half-life
~24 days (consistent with IgG antibodies)
Related guidelines
Other Unclassified drugs
Ask House about atoltivimab
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e, Harrison 22e·Updated: 2026-05-10